SEARCH

SEARCH BY CITATION

References

  • 1
    Braunwald E., Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000;102:IV1423.
  • 2
    Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89118.
  • 3
    Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:10019.
  • 4
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:722.
  • 5
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:13839.
  • 6
    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:134957.
  • 7
    Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol> or =125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002;90:1479.
  • 8
    Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:24954.
  • 9
    Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail 2006;12:66474.
  • 10
    Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:224861.
  • 11
    Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:21624.
  • 12
    Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963;27:28293.
  • 13
    Bing OH, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 1995;27:38396.
  • 14
    Boluyt MO, Bing OH, Lakatta EG. The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Eur Heart J 1995;16(Suppl N):1930.
  • 15
    Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997;96:400210.
  • 16
    Bing OH, Conrad CH, Boluyt MO, Robinson KG, Brooks WW. Studies of prevention, treatment and mechanisms of heart failure in the aging spontaneously hypertensive rat. Heart Fail Rev 2002;7:7188.
  • 17
    Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979;575:26676.
  • 18
    McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B32B.
  • 19
    Loch D, Levick S, Hoey A, Brown L. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2006;47:396404.
  • 20
    Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003;42:10917.
  • 21
    Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005;66:46271.
  • 22
    Tarhzaoui K, Valensi P, Leger G, Cohen-Boulakia F, Lestrade R, Behar A. Rosuvastatin positively changes nerve electrophysiology in diabetic rats. Diabetes Res Clin Pract 2008;80:33543.
  • 23
    Park JK, Mervaala EM, Muller DN, Menne J, Fiebeler A, Luft FC et al. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. J Hypertension 2009;27:599605.
  • 24
    Fenning A, Harrison G, Rose’meyer R, Hoey A, Brown L. L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol 2005;289:140816.
  • 25
    Brown L, Fenning A, Chan V, Loch D, Wilson K, Anderson B et al. Echocardiographic assessment of cardiac structure and function in rats. Heart Lung Circ 2002;11:16773.
  • 26
    Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994;89:34554.
  • 27
    Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta 1967;18:26773.
  • 28
    Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009;15:46778.
  • 29
    Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005;46:197885.
  • 30
    Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009;112:412.
  • 31
    Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:9825.
  • 32
    Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:86873.
  • 33
    Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci (Lond) 2005;108:34955.
  • 34
    Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:2418.
  • 35
    Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002;55:7682.
  • 36
    Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996;28:26975.
  • 37
    Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:138893.
  • 38
    Habibi J, Whaley-Connell A, Qazi MA, Hayden MR, Cooper SA, Tramontano A et al. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases oxidative stress and remodelling in Ren2 transgenic rats. Endocrinology 2007;148:21818.
  • 39
    Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:96874.
  • 40
    Cerbai E, Crucitti A, Sartiani L, De Paoli P, Pino R, Rodriguez ML et al. Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes. Cardiovasc Res 2000;45:38896.
  • 41
    Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42:27083.
  • 42
    Cerbai E, De Paoli P, Sartiani L, Lonardo G, Mugelli A. Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats. J Cardiovasc Pharmacol 2003;41:80412.